A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
The increase in total revenues was driven primarily by sales of Natera's Panorama and Horizon reproductive health tests.
CareDx first sued Natera in April 2019, accusing the company of trying to mislead patients and clinicians about the superiority of its Prospera transplant test.
Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.
News items for the in vitro diagnostics industry for the week of Jan. 27, 2020.
Natera alleged that certain cell-free DNA-based oncology products sold by Archer Dx infringe its US Patent 10,538,814, which was issued earlier this month.
Natera discussed its cancer and transplant rejection testing businesses, while Exact Sciences explained how it will benefit from its Genomic Health acquisition.
The patent, which was awarded Jan. 7, covers cell-free DNA-based diagnostic methods, including those used in transplant medicine.
The multi-center registry study aims to measure the clinical impact of serial testing with Signatera in patients with stage II or stage III colorectal cancer.
The magistrate did recommend that the court dismiss two counts made against Natera with respect to trademark disparagement and unfair trade practices.